Article | January 10, 2020

Securing Today's Biomanufacturing Supply Chain Using Transformative Supply

Source: Cytiva

By Sofie Stille, GM BioProcess Resins & Technologies and Elles Steensma, Program leader, GE

Drug packaging logistics 450x300

Today, biologics represent a $250 billion industry, which is two times what it was worth only 10 years ago.1 It is estimated that in just four to five years biologics will make up around 50 percent of the 100 top-selling drugs, corresponding to nearly 30 percent of the total market.2 Though monoclonal antibodies are expected to continue dominating the market, a more diversified pipeline that includes, for example, DNA and RNA molecules and cell and gene therapies is anticipated as the growth continues.

Responding to the rapidly changing requirements of these novel therapies means tackling some of the biggest challenges that have the potential to hinder this evolution. One such area is sustainability and security in the biopharmaceutical supply chain.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: